Phase i Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients

Clinical Breast Cancer

Volumn 16, Issue 2, 2016, Pages 82-86

  Tan, Winston W ^a   Allred, Jacob B ^b   Moreno Aspitia, Alvaro ^a   Northfelt, Donald W ^c   Ingle, James N ^b   Goetz, Matthew P ^b   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Aromatase refractory; Endocrine resistant breast cancer; Histone deacetylase inhibitors; Phase I study

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FULVESTRANT; LETROZOLE; PANOBINOSTAT; TAMOXIFEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; NITRILE; PROGESTERONE RECEPTOR; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLADDER INFECTION; BLEEDING; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTHYROIDISM; INFECTION; LEUKOCYTE COUNT; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; DRUG ADMINISTRATION; ENZYME IMMUNOASSAY; FOLLOW UP; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; INDOLES; LYMPHATIC METASTASIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRIAZOLES;

EID: 84960290488     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.11.003     Document Type: Article

References (13)

1. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 2006 769 784
2. K.B. Glaser HDAC inhibitors: clinical update and mechanism-based potential Biochem Pharmacol 74 2007 659 671
3. R.W. Johnstone, and J.D. Licht Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 2003 13 18
4. T. Kuukasjarvi, J. Kononen, H. Helin, K. Holli, and J. Isola Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 1996 2584 2589
5. G.J. Sabnis, O. Goloubeva, L.F. Macedo, and et al. Combination of HDACi entinostat (SNDX-275) with letrozole provides control over tumor growth in MDA-MB-231 xenograft model Cancer Res 69 2 suppl 2009 abstract 6128
6. Q. Zhou, P. Atadja, and N.E. Davidson Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation Cancer Biol Ther 6 2007 64 69
7. C.R. Tate, L.V. Rhodes, H.C. Segar, and et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat Breast Cancer Res 14 2012 R79
8. J.C. Keen, L. Yan, K.M. Mack, and et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine Breast Cancer Res Treat 81 2003 177 186
9. X. Yang, A.T. Ferguson, S.J. Nass, and et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition Cancer Res 60 2000 6890 6894
10. M. Kubo., N. Kanaya., K. Petrossian., and et al. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat) Breast Cancer Res Treat 137 2013 93 107
11. T.H. Luu, R.J. Morgan, L. Leong, and et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study Clin Cancer Res 14 2008 7138 7142
12. P.N. Munster, K.T. Thurn, S. Thomas, and et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Br J Cancer 104 2011 1828 1835
13. D.A. Yardley, R.R. Ismail-Khan, B. Melichar, and et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor J Clin Oncol 31 2013 2128 2135